Jesus Blazquez

List of Publications by Year
in descending order

128 papers	8,555 citations	47006 47 h-index	49909 87 g-index
131 all docs	131 docs citations	131 times ranked	7832 citing authors

#	Article	IF	Citations
1	Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in <i>Escherichia coli</i>. Journal of Antimicrobial Chemotherapy, 2022, 77, 641-645.	3.0	5
2	Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of <i>Escherichia coli</i>. Journal of Antimicrobial Chemotherapy, 2021, 76, 338-344.	3.0	7
3	Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
4	Synergistic Quinolone Sensitization by Targeting the <i>recA</i> SOS Response Gene and Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
5	Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	3
6	Control of Genome Stability by EndoMS/NucS-Mediated Non-Canonical Mismatch Repair. Cells, 2021, 10, 1314.	4.1	6
7	Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination. Antibiotics, 2020, 9, 802.	3.7	7
8	Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2020, 75, 2066-2075.	3.0	6
9	Specificity and mutagenesis bias of the mycobacterial alternative mismatch repair analyzed by mutation accumulation studies. Science Advances, 2020, 6, eaay4453.	10.3	30
10	4-Amino-1,2,4-triazole-3-thione as a Promising Scaffold for the Inhibition of Serine and Metallo-Î²-Lactamases. Pharmaceuticals, 2020, 13, 52.	3.8	13
11	Effect of subinhibitory concentrations of ampicillin on Listeria monocytogenes. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 72-75.	0.5	1
12	Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant Escherichia coli. Journal of Antimicrobial Chemotherapy, 2019, 74, 66-73.	3.0	17
13	Seawater salt-trapped Pseudomonas aeruginosa survives for years and gets primed for salinity tolerance. BMC Microbiology, 2019, 19, 142.	3.3	11
14	Phenylboronic Acids Probing Molecular Recognition against Class A and Class C Î²-lactamases. Antibiotics, 2019, 8, 171.	3.7	9
15	N-acetylcysteine blocks SOS induction and mutagenesis produced by fluoroquinolones in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2019, 74, 2188-2196.	3.0	33
16	Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPCâ€2: A Step against Bacterial Resistance. ChemMedChem, 2018, 13, 713-724.	3.2	24
17	Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
18	Nanostructured hybrid device mimicking bone extracellular matrix as local and sustained antibiotic delivery system. Microporous and Mesoporous Materials, 2018, 256, 165-176.	4.4	14

#	Article	IF	Citations
19	In silico identification and experimental validation of hits active against KPC-2 Î²-lactamase. PLoS ONE, 2018, 13, e0203241.	2.5	9
20	Antibiotic-Induced Genetic Variation: How It Arises and How It Can Be Prevented. Annual Review of Microbiology, 2018, 72, 209-230.	7.3	81
21	Clay-induced DNA breaks as a path for genetic diversity, antibiotic resistance, and asbestos carcinogenesis. Scientific Reports, 2018, 8, 8504.	3.3	8
22	Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 2770-2776.	3.0	19
23	Parallel Evolution of High-Level Aminoglycoside Resistance in Escherichia coli Under Low and High Mutation Supply Rates. Frontiers in Microbiology, 2018, 9, 427.	3.5	28
24	Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2018, 73, 2960-2968.	3.0	28
25	Molecular insights into fosfomycin resistance in<i>Escherichia coli</i>. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw573.	3.0	29
26	Plasmidic <i>qnr</i> Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	8
27	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. Clinical Microbiology and Infection, 2017, 23, 325-331.	6.0	38
28	A non-canonical mismatch repair pathway in prokaryotes. Nature Communications, 2017, 8, 14246.	12.8	100
29	Design, synthesis and biological evaluation of non-covalent AmpC Î²-lactamases inhibitors. Medicinal Chemistry Research, 2017, 26, 975-986.	2.4	11
30	Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
31	Synergistic activity of fosfomycin, Î²-lactams and peptidoglycan recycling inhibition against<i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2017, 72, 448-454.	3.0	25
32	Quinolone Resistance Reversion by Targeting the SOS Response. MBio, 2017, 8, .	4.1	54
33	Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-Î²-lactamases. Scientific Reports, 2017, 7, 17716.	3.3	35
34	Cellular Response to Ciprofloxacin in Low-Level Quinolone-Resistant Escherichia coli. Frontiers in Microbiology, 2017, 8, 1370.	3.5	21
35	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS ONE, 2017, 12, e0181932.	2.5	32
36	Intrapopulation variability in mutator prevalence among urinary tract infection isolates of Escherichia coli. Clinical Microbiology and Infection, 2016, 22, 566.e1-566.e7.	6.0	20

#	Article	IF	Citations
37	Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli. Antimicrobial Agents and Chemotherapy, 2016, 60, 4252-4258.	3.2	20
38	Determinants of Genetic Diversity of Spontaneous Drug Resistance in Bacteria. Genetics, 2016, 203, 1369-1380.	2.9	7
39	Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1767-1778.	3.2	170
40	Can Clays in Livestock Feed Promote Antibiotic Resistance and Virulence in Pathogenic Bacteria?. Antibiotics, 2015, 4, 299-308.	3.7	9
41	Bypass of genetic constraints during mutator evolution to antibiotic resistance. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20142698.	2.6	45
42	High Recombinant Frequency in Extraintestinal PathogenicEscherichia coliStrains. Molecular Biology and Evolution, 2015, 32, 1708-1716.	8.9	21
43	<i>N</i>-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism. Antimicrobial Agents and Chemotherapy, 2015, 59, 3246-3251.	3.2	16
44	The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to Î²-Lactams, Fitness, Biofilm Growth, and Global Regulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 5084-5095.	3.2	56
45	Antibiotics and antibiotic resistance: A bitter fight against evolution. International Journal of Medical Microbiology, 2013, 303, 293-297.	3.6	171
46	Î²-lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity. Nature Communications, 2013, 4, 1610.	12.8	320
47	Lysine Trimethylation of EF-Tu Mimics Platelet-Activating Factor To Initiate Pseudomonas aeruginosa Pneumonia. MBio, 2013, 4, e00207-13.	4.1	42
48	Mutational Spectrum Drives the Rise of Mutator Bacteria. PLoS Genetics, 2013, 9, e1003167.	3.5	46
49	The Animal Food Supplement Sepiolite Promotes a Direct Horizontal Transfer of Antibiotic Resistance Plasmids between Bacterial Species. Antimicrobial Agents and Chemotherapy, 2013, 57, 2651-2653.	3.2	34
50	Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics, 2013, 2, 217-236.	3.7	151
51	Genomewide Overexpression Screen for Fosfomycin Resistance in Escherichia coli: MurA Confers Clinical Resistance at Low Fitness Cost. Antimicrobial Agents and Chemotherapy, 2012, 56, 2767-2769.	3.2	48
52	Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of Pseudomonas aeruginosa in Chronic Lung Infections. Journal of Infectious Diseases, 2012, 205, 121-127.	4.0	61
53	Exposure to diverse antimicrobials induces the expression of qnrB1, qnrD and smaqnr genes by SOS-dependent regulation. Journal of Antimicrobial Chemotherapy, 2012, 67, 2854-2859.	3.0	32
54	Simple DNA transformation in Pseudomonas based on the Yoshida effect. Journal of Microbiological Methods, 2012, 89, 95-98.	1.6	13

#	Article	IF	Citations
55	Antimicrobials as promoters of genetic variation. Current Opinion in Microbiology, 2012, 15, 561-569.	5.1	161
56	The Escherichia coli SOS Gene dinF Protects against Oxidative Stress and Bile Salts. PLoS ONE, 2012, 7, e34791.	2.5	36
57	Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. Journal of Antimicrobial Chemotherapy, 2011, 66, 531-538.	3.0	139
58	Estimating mutation rates in low-replication experiments. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 714, 26-32.	1.0	15
59	The K+ uptake regulator TrkA controls membrane potential, pH homeostasis and multidrug susceptibility in Mycobacterium smegmatis. Journal of Antimicrobial Chemotherapy, 2011, 66, 1489-1498.	3.0	34
60	Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. Antimicrobial Agents and Chemotherapy, 2011, 55, 4560-4568.	3.2	58
61	Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections. PLoS ONE, 2010, 5, e10193.	2.5	37
62	Frequency of Spontaneous Resistance to Fosfomycin Combined with Different Antibiotics in <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 4948-4949.	3.2	24
63	A MATE-Family Efflux Pump Rescues the Escherichia coli 8-Oxoguanine-Repair-Deficient Mutator Phenotype and Protects Against H2O2 Killing. PLoS Genetics, 2010, 6, e1000931.	3.5	33
64	The <i>Pseudomonas aeruginosa pfpI</i> Gene Plays an Antimutator Role and Provides General Stress Protection. Journal of Bacteriology, 2009, 191, 844-850.	2.2	48
65	The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in <i>Pseudomonas aeruginosa</i>. Journal of Bacteriology, 2009, 191, 6968-6974.	2.2	102
66	Î2-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. PLoS Pathogens, 2009, 5, e1000353.	4.7	258
67	Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology (United Kingdom), 2009, 155, 1050-1057.	1.8	124
68	Side effects of antibiotics on genetic variability. FEMS Microbiology Reviews, 2009, 33, 531-538.	8.6	89
69	Effect of Subinhibitory Concentrations of Antibiotics on Intrachromosomal Homologous Recombination in <i>Escherichia coli</i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 3411-3415.	3.2	74
70	The evolution of contact-dependent inhibition in non-growing populations of<i>Escherichia coli</i>. Proceedings of the Royal Society B: Biological Sciences, 2008, 275, 3-10.	2.6	33
71	A novel role for RecA under non-stress: promotion of swarming motility in Escherichia coli K-12. BMC Biology, 2007, 5, 14.	3.8	69
72	Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Molecular Microbiology, 2007, 64, 83-93.	2.5	115

#	Article	IF	Citations
73	Multidrug-resistant<i>Mycobacterium tuberculosis</i>, Bangui, Central African Republic. Emerging Infectious Diseases, 2006, 12, 1454-1456.	4.3	16
74	Determination of the structure of a hybrid between 2-(1,4-benzoquinone)acetic acid and a linear peptide by electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 512-516.	1.5	3
75	In vitro plasmid-encoded resistance to quinolones. FEMS Microbiology Letters, 2006, 154, 271-276.	1.8	10
76	PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Molecular Microbiology, 2006, 62, 84-99.	2.5	97
77	Identification of Nudix Hydrolase Family Members with an Antimutator Role in Mycobacterium tuberculosis and Mycobacterium smegmatis. Journal of Bacteriology, 2006, 188, 3159-3161.	2.2	38
78	Autogenous and nonautogenous control of response in a genetic network. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12718-12723.	7.1	57
79	SOS-Independent Induction of dinB Transcription by Î²-Lactam-Mediated Inhibition of Cell Wall Synthesis in Escherichia coli. Journal of Bacteriology, 2005, 187, 1515-1518.	2.2	105
80	Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrobial Agents and Chemotherapy, 2004, 48, 4226-4233.	3.2	138
81	Aza-boronic acids as non-Î²-lactam inhibitors of AmpC-Î²-lactamase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3979-3983.	2.2	14
82	Recognition and Resistance in TEM Î²-Lactamaseâ€. Biochemistry, 2003, 42, 8434-8444.	2.5	47
83	Nanomolar Inhibitors of AmpC Î²-Lactamase. Journal of the American Chemical Society, 2003, 125, 685-695.	13.7	123
84	Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance. Clinical Infectious Diseases, 2003, 37, 1201-1209.	5.8	181
85	Mutations in Putative Mutator Genes of<i>Mycobacterium tuberculosis</i>Strains of the W-Beijing Family. Emerging Infectious Diseases, 2003, 9, 838-845.	4.3	240
86	Very Low Cefotaxime Concentrations Select for Hypermutable Streptococcus pneumoniae Populations. Antimicrobial Agents and Chemotherapy, 2002, 46, 528-530.	3.2	41
87	Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?. Current Drug Targets, 2002, 3, 345-349.	2.1	57
88	The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Molecular Microbiology, 2002, 43, 1641-1650.	2.5	243
89	Characterization of the GO system ofPseudomonas aeruginosa. FEMS Microbiology Letters, 2002, 217, 31-35.	1.8	47
90	Structure-based design and in-parallel synthesis of inhibitors of AmpC Î²-lactamase. Chemistry and Biology, 2001, 8, 593-610.	6.0	45

#	Article	IF	Citations
91	Antibiotic resistance in hospital infections: the role of newer cephalosporins. Clinical Microbiology and Infection, 2000, 6, 95-97.	6.0	1
92	Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. Aids, 2000, 14, F1-F7.	2.2	80
93	Concentration-Dependent Selection of Small Phenotypic Differences in TEM Î²-Lactamase-Mediated Antibiotic Resistance. Antimicrobial Agents and Chemotherapy, 2000, 44, 2485-2491.	3.2	114
94	Selection of Naturally Occurring Extended-Spectrum TEM Î²-Lactamase Variants by Fluctuating Î²-Lactam Pressure. Antimicrobial Agents and Chemotherapy, 2000, 44, 2182-2184.	3.2	57
95	ACI-1 from Acidaminococcus fermentans : Characterization of the First Î²-Lactamase in Anaerobic Cocci. Antimicrobial Agents and Chemotherapy, 2000, 44, 3144-3149.	3.2	24
96	Biological Cost of AmpC Production for Salmonella enterica Serotype Typhimurium. Antimicrobial Agents and Chemotherapy, 2000, 44, 3137-3143.	3.2	90
97	High Frequency of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Infection. Science, 2000, 288, 1251-1253.	12.6	1,322
98	Molecular Markers Demonstrate that the First Described Multidrug-Resistant <i>Mycobacterium bovis</i> Outbreak Was Due to <i>Mycobacterium tuberculosis</i>. Journal of Clinical Microbiology, 1999, 37, 971-975.	3.9	30
99	Mycobacterium tuberculosis subsp. caprae subsp. nov.: A taxonomic study of a new member of the Mycobacterium tuberculosis complex isolated from goats in Spain. International Journal of Systematic and Evolutionary Microbiology, 1999, 49, 1263-1273.	1.7	152
100	The complexed structure and antimicrobial activity of a nonâ€Î²â€lactam inhibitor of AmpC Î²â€lactamase. Protein Science, 1999, 8, 2330-2337.	7.6	66
101	An extended-spectrum AmpC-type ÃŽÂ²-lactamase obtained by in vitro antibiotic selection. FEMS Microbiology Letters, 1998, 165, 85-90.	1.8	33
102	Identification as Mycobacterium tuberculosis of previously described M bovis multidrug-resistant strains. Lancet, The, 1998, 351, 758.	13.7	6
103	Structure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC Î²-Lactamase. Journal of Medicinal Chemistry, 1998, 41, 4577-4586.	6.4	139
104	Antibioticâ€Selective Environments. Clinical Infectious Diseases, 1998, 27, S5-S11.	5.8	197
105	Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. Aids, 1998, 12, F131-F135.	2.2	117
106	A237T as a Modulating Mutation in Naturally Occurring Extended-Spectrum TEM-Type Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 1998, 42, 1042-1044.	3.2	33
107	Allele-Specific PCR Method Based on <i>pncA</i> and <i>oxyR</i> Sequences for Distinguishing <i>Mycobacterium bovis</i> from <i>Mycobacterium tuberculosis</i> : Intraspecific <i>M. bovis pncA</i> Sequence Polymorphism. Journal of Clinical Microbiology, 1998, 36, 239-242.	3.9	71
108	Selection of very small differences in bacterial evolution. International Microbiology, 1998, 1, 295-300.	2.4	16

#	Article	IF	Citations
109	Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. Aids, 1997, 11, 1237-1242.	2.2	76
110	Evolution of antibiotic resistance. Trends in Ecology and Evolution, 1997, 12, 482-487.	8.7	126
111	Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet, The, 1997, 350, 1738-1742.	13.7	108
112	H-NS and RpoS regulate emergence of Lac Ara+ mutants of Escherichia coli MCS2. Journal of Bacteriology, 1997, 179, 4620-4622.	2.2	44
113	The Antibiotic Selective Process: Concentrationâ€Specific Amplification of Lowâ€Level Resistant Populations. Novartis Foundation Symposium, 1997, 207, 93-111.	1.1	27
114	Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. Journal of Clinical Microbiology, 1997, 35, 1390-1393.	3.9	85
115	Cyclic AMP receptor protein positively controls gyrA transcription and alters DNA topology after nutritional upshift in Escherichia coli. Journal of Bacteriology, 1996, 178, 3331-3334.	2.2	47
116	Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) beta-lactamase. Antimicrobial Agents and Chemotherapy, 1996, 40, 2434-2436.	3.2	53
117	hns mutant unveils the presence of a latent haemolytic activity in Escherichia coli K-12. Molecular Microbiology, 1996, 19, 909-910.	2.5	18
118	Characterization of a Nosocomial Outbreak Involving an Epidemic Plasmid Encoding for TEM-27 in Salmonella enterica Subspecies enterica Serotype Othmarschen. Journal of Infectious Diseases, 1996, 174, 1015-1020.	4.0	52
119	New extended-spectrum TEM-type beta-lactamase from Salmonella enterica subsp. enterica isolated in a nosocomial outbreak. Antimicrobial Agents and Chemotherapy, 1995, 39, 458-461.	3.2	72
120	Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM beta-lactamases. Antimicrobial Agents and Chemotherapy, 1995, 39, 145-149.	3.2	63
121	In-vitro synergy between aminoglycosides deployed against Staphylococcus spp. harbouring a 6â€²-aminoglycoside acetyltransferase, 2â€³-aminoglycoside phosphotransferase enzyme. Journal of Antimicrobial Chemotherapy, 1994, 33, 747-755.	3.0	3
122	Non-canonical mechanisms of antibiotic resistance. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 1015-1022.	2.9	17
123	Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy, 1993, 37, 2059-2063.	3.2	168
124	Bleomycin increases amikacin and streptomycin resistance in Escherichia coli harboring transposon Tn5. Antimicrobial Agents and Chemotherapy, 1993, 37, 1982-1985.	3.2	7
125	PCR and hemodialysis patients. Clinical Nephrology, 1993, 40, 121-2.	0.7	1
126	Mutations in the aphA-2 gene of transposon Tn5 mapping within the regions highly conserved in aminoglycoside-phosphotransferases strongly reduce aminoglycoside resistance. Molecular Microbiology, 1991, 5, 1511-1518.	2.5	26

#	Article	IF	Citations
127	Bleomycin-kanamycin resistance as a marker of the presence of transposon Tn5 in clinical strains ofEscherichia coli. European Journal of Clinical Microbiology and Infectious Diseases, 1989, 8, 995-998.	2.9	6
128	A clinical isolate of transposon Tn5 expressing streptomycin resistance in Escherichia coli. Journal of Bacteriology, 1988, 170, 1275-1278.	2.2	10